Navigation Links
The same genetic defect causes Pompe disease in both humans and dogs
Date:2/15/2013

Pompe disease, a severe glycogen storage disease appearing in Lapphunds is caused by a genetic defect in acid α-glucosidase gene. The same genetic mutation also causes the equivalent disease in humans. Based on this finding, canine Pompe disease can now be diagnosed with a genetic test.

This research was completed at the Canine Genetics Research Group lead by professor Hannes Lohi in the University of Helsinki and Folkhlsan Research Center in Finland and will be published in PLOS ONE on February 14, 2013.

Human Pompe disease is caused by complete or partial deficiency of the acidic α-glucosidase enzyme. In humans, over 300 mutations have been discovered in the gene encoding this enzyme. Pompe disease is recessively inherited, therefore requiring the inheritance of the defected gene from both father and mother. Typically, human patients have two different mutations; one is inherited from father and the other from mother. If both mutations cause severe defect to the enzyme, the enzymatic activity is completely lost. This leads to infantile onset Pompe disease.

The average onset of the infantile disease is before two months of age and the affected children often die before the age of one year. Typical symptoms are floppy appearance, difficulties in sucking and swallowing, an enlarged heart which may lead to heart failure, difficulties in breathing, and respiratory infections. There is no cure for the disease, but enzyme replacement therapy relieves the symptoms and prolongs the patient's lifespan.

Canine Pompe disease is known to occur in Swedish Lapphunds and in this study it was revealed also from Finnish Lapphunds. Both the affected puppies and infantile onset patients lack functional acid α-glucosidase enzyme. Normally this enzyme breaks down the stored glycogen into glucose inside the lysosomes. When the α-glucosidase enzyme is not working properly, glycogen accumulates inside the cells of
'/>"/>

Contact: Hannes Lohi
hannes.lohi@helsinki.fi
358-919-125-085
University of Helsinki
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Head, Body Lice Are Genetically Very Similar
4. Certain Genetic Regions May Be Tied to Osteoporosis
5. Study of half siblings provides genetic clues to autism
6. Genetic variants, tobacco exposure and lung cancer risk
7. Research Gets Closer to Genetic Roots of Glaucoma
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
10. Some women may be genetically predisposed to smoking-related hot flashes
11. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The same genetic defect causes Pompe disease in both humans and dogs
(Date:5/29/2015)... NJ (PRWEB) May 30, 2015 ... ever changing local and federal regulations, we provide ... of their patients who are suffering from pain, ... says Srinivas Nalamachu, MD, professor of rehabilitation medicine ... Institute in Overland Park, Kansas. , A new ...
(Date:5/29/2015)... 2015 What does community do? , ... community comes together to plant gardens, to teach young ... awareness of critical issues. Community invites everyone to help ... , "What Community Does" was commissioned by The Denver ... and released during the foundation’s Annual Celebration in May. ...
(Date:5/29/2015)... Rhode Island (PRWEB) May 29, 2015 ... 7, 2015. The event, now closed to new registration, ... Fort Adams. This exciting competitive running event demonstrates ... organizations to create a public benefit – in this ... scenic coastal views around the famed Ocean Drive and ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... 2015 According to a recent HealthDay article, ... workers has a substance abuse problem - the data, which ... adults with full-time jobs, revealed that 9.5% of those workers ... (1) The National Council on Alcoholism and Drug Dependence (NCAAD) ... an estimated 70% of the 14.8 million illicit drug users ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4
... Caused Public Health CrisisEditor,s Note: Complete report including ... . WASHINGTON, Jan. 13 The American Lung ... 2008 report today, which includes a report ... federal laws to protect citizens from tobacco caused ...
... groundbreaking case that could,affect one-third of American families, Cook ... a 10 month old child with a severe heart,condition ... also gave the,father custody of his 3 year old ... unusual because most courts have not recognized stepfathers,as having ...
... Tenn., Jan. 13 The National Eczema Association (NEA) ... and Theraplex Clear Lotion .The NEA Seal ... Sensitive-Skin Education (EASE) program, which is intended to improve ... eczema and sensitive skin. "These products met our criteria ...
... meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical has ... season beginning in August. , ... (Vocus) January 13, ... Flu Vaccine for the 2009-2010 flu season. They ...
... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ... Julia M. Fisher, Western Medical Product Manager. , ... Westlake, OH (PRWEB) ... the MLC, Mini Click Oxygen Regulator. "In these tough times, the MLC ...
... New research out of Wake Forest University Baptist Medical ... used to relieve symptoms of cough and congestion, may ... , The study appears in this month,s issue ... American College of Chest Physicians, and reports that the ...
Cached Medicine News:Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 2Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 3Health News:American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Low Cost Oxygen Regulator: Pay Less For Quality 2Health News:Popular cold and cough treatment may create respiratory distress in young children 2Health News:Popular cold and cough treatment may create respiratory distress in young children 3
(Date:5/29/2015)... May 29, 2015 /CNW/ - Covalon Technologies Ltd. (the ... technologies company, is delighted to announce its financial ... 2015, which includes revenue for three months of ... $264,340. Revenue from advanced wound care product sales for ... increased 24% to $1,742,672 compared to $1,400,065 for ...
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and Company ... ) today announced that they have entered into a ... efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, ... Receptor 2 antiangiogenic cancer medicine. The planned study will ... advanced solid tumors. The Phase I study ...
(Date:5/28/2015)... and Company (NYSE: LLY ) announced today the pricing ... to $1.6 billion aggregate principal amount of certain of its ... and did not validly withdraw, their notes on or before ... on May 27, 2015 (the early tender date), and which ... the total consideration. The total consideration for each series of ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... May 02, 2007 /PRNewswire/ -- Ceregene, Inc.,today presented interim ... gene therapy product designed to deliver nerve growth,factor (NGF) ... follow-up, the results for the six patients who received,CERE-110 ... the,therapy was well tolerated, and an interim analysis suggested ...
... CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - ... sclerosis (RRMS),patients treated with COPAXONE(R) (glatiramer ... experienced a,90 percent reduction in magnetic ... their baseline. These benefits were,achieved early ...
Cached Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
1.2% Tryptone, 2.4% Yeast Extract, 1.6% Glycerol, 100 ml of 10x Phosphate buffer supplement....
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
Medicine Products: